January 31, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Meridian Bioscience, Inc. (NASDAQ:VIVO) shares over potential securities laws violations by Meridian Bioscience, Inc. and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Meridian Bioscience, Inc. (NASDAQ:VIVO) concerning whether a series of statements by Meridian Bioscience, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Meridian Bioscience, Inc. reported that its Total Revenue rose from $194.83 million for the 12 months period that ended on September 30, 2015 to over $196.08 million for the 12 months period that ended on September 30, 2016 and that its Net Income for those respective time periods declined from $35.54 million to $32.23 million.


On January 25, 2017, Meridian Bioscience, Inc announced negative first-quarter 2017 fiscal year financial results, revised its previously issued revenue guidance for the 2017 fiscal year downwards, and announced that the Board of Directors reduced the annual indicated dividend rate.
Shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) declined on January 25, 2017 to $10.75 per share.